Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

Mes dernières consult.
Most popular
Financials ($)
Sales 2017 11 990 M
EBIT 2017 3 405 M
Net income 2017 1 265 M
Debt 2017 13 788 M
Yield 2017 -
Sales 2018 12 746 M
EBIT 2018 3 762 M
Net income 2018 1 967 M
Debt 2018 11 658 M
Yield 2018 -
P/E ratio 2017 17,08
P/E ratio 2018 10,73
EV / Sales2017 2,92x
EV / Sales2018 2,58x
Capitalization 21 199 M
More Financials
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom. 
02/28Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/14 MYLAN : Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Pa..
12/11 MYLAN : Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to ..
12/05DJRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
12/04 MYLAN NV : Today’s Research Reports on Stocks to Watch: Mylan and Nutanix
12/04 MYLAN : and Aspen Announce Launch of Generic Busulfex® Injection
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
12/01 MYLAN : U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar..
12/01 MYLAN : FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan'..
11/30 MYLAN : European Medicines Agency Accepts Marketing Authorization Applications f..
More news
Sector news : Pharmaceuticals - NEC
12:05a Wall Street falls as investors fret about tax bill passage
12/14 TSX in broad retreat led by Cenovus, other energy stocks
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Pharm to lay off a quarter of workforce, suspen..
12/14DJTEVA PHARMACEUTICAL INDUSTRIES : to Cut 14,000 Jobs, Suspend Dividend -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 43,7 $
Spread / Average Target 10%
EPS Revisions
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214